Patients are searching for this trial right now

This page is already ranking on Google. Activate it to start receiving pre-qualified patient leads directly in your inbox.

14-day free trial · $44/mo after · Cancel anytime · Money-back guarantee

NCT02989948 · Yale University

Physician-Modified Fenestrated and Branched Aortic Endografting for TAAA

What this study is about

The primary clinical objective of this study is to evaluate the safety and effectiveness of a physician-modified, fenestrated and branched aortic endoprosthesis for the treatment of thoracoabdominal aortic aneurysms (TAAAs).

View original scientific description

The primary clinical objective of this study is to evaluate the safety and effectiveness of a physician-modified, fenestrated and branched aortic endoprosthesis for the treatment of thoracoabdominal aortic aneurysms (TAAAs). The goal of the primary analysis is to demonstrate both the safety and effectiveness of using a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft as compared to previously published results of open surgical replacement of the aneurysmal aorta.

Who can participate

This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.

Inclusion criteria

  • Must be a man or woman 50 years of age or older by the date of informed consent.
  • Must have a thoracoabdominal aortic aneurysm of any Crawford classification (extent I-V) that extends no more proximal than the left subclavian artery.
  • Must have an aneurysm size that meets standard indications for surgical repair (6.0 cm in maximum diameter in the descending thoracic aorta, or 5.5 cm in maximum diameter in the abdominal aorta).
  • Must be considered, in the judgment of the S-I, to be a high risk candidate for open surgical repair.
  • Must not be a candidate for repair under the Instructions for Use of a commercially available, FDA-approved endovascular graft.
  • Must be able to provide informed consent.
  • Must be able to comply with the five year study assessment schedule of events.
  • Must have a non-aneurysm-related life expectancy, in the judgment of the S-I, of greater than 2 years. MAIN ARM -

Exclusion criteria

  • Aneurysm due to acute or chronic dissection, intramural hematoma, penetrating aortic ulceration, pseudoaneurysm, mycotic aneurysm, or traumatic transection.
  • Ruptured or acutely symptomatic aortic aneurysm.
  • Known connective tissue disorder.
  • Imaging demonstrating any of the following:
  • Lack of 20 mm non-aneurysmal proximal seal zone (zone 3, or zone 2 with a carotid-subclavian bypass or transposition).
  • Lack of 15 mm non-aneurysmal distal seal zone(s) (aortic, common iliac, or external iliac).
  • Branch vessel target (renal, superior mesenteric, or celiac) \< 5 mm or \> 10 mm in average diameter.
  • Untreated left subclavian artery stenosis or occlusion.
  • Untreated unilateral or bilateral hypogastric artery occlusion.
  • Signs that the inferior mesenteric artery is indispensable.
  • Have branching, duplication, aneurysm, or untreatable stenosis of the celiac, superior mesenteric artery, or renal arteries that would preclude implantation of the investigational devices.
  • Known sensitivities or allergies to stainless steel, PTFE, polyester, polypropylene, nitinol, or gold.
  • History of anaphylaxis to contrast, with inability to prophylax appropriately.
  • Have uncorrectable coagulopathy.
  • Have unstable angina.
  • Have a body habitus that would inhibit X-ray visualization of the aorta.
  • Have a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned ≤30 days of the endovascular repair.
  • Known to be participating in any other clinical study which may affect performance of this device.
  • Known, visible, or suspected pregnancy, confirmed with a Urine Pregnancy Test (UPT)
  • Contraindication to oral antiplatelet therapy.
  • Prisoners or those on alternative sentencing.
  • Known systemic infection with potential for endovascular graft infection.
  • Anticipated need for MRI scanning within 3 months of insertion of investigational product.
  • Other conditions or comorbidities that, in the opinion of the S-I, would exclude the patient. EXPANDED ACCESS ARM - Inclusion Criteria
  • Must be a man or woman 50 years of age or older by the date of informed consent
  • Must have a thoracic, thoracoabdominal, or abdominal aortic aneurysm that necessitates coverage of one or more visceral vessels (celiac, superior mesenteric, or renals) for establishment of proximal and/or distal seal.
  • Must have an aneurysm size that meets standard size indications for surgical repair (6.0 cm in maximum diameter in the descending thoracic aorta, or 5.5 cm in maximum diameter in the abdominal aorta); or, in the judgment of the S-I, has aneurysm characteristics that portend a high risk of near-term rupture
  • Must be considered, in the judgement of the S-I, to be a high risk candidate for open surgical repair
  • Must not be a candidate for repair under the Instructions for Use of a commercially available, FDA-approved endovascular graft
  • Patient must be able to provide informed consent
  • Must be able to comply with the five year study assessment schedule of events
  • Must have a non-aneurysm-related life expectancy, in the judgement of the S-I, of greater than 2 years EXPANDED ACCESS ARM - Exclusion Criteria
  • Known or suspected mycotic aneurysm
  • Ruptured aneurysm with hemodynamic instability
  • Known connective tissue disorder
  • Imaging demonstrating any of the following:
  • Lack of 20 mm non-aneurysmal proximal seal zone (in either native aorta, elephant trunk graft, or aortic arch endograft)
  • Lack of 15 mm non-aneurysmal distal seal zone(s) (in either native aortoiliac vessels, prosthetic aortoiliac grafts, or aortoiliac endografts)
  • Branch vessel target (renal, superior mesenteric, or celiac) \> 10 mm in average diameter
  • Known sensitivities or allergies to stainless steel, PTFE, polyester, polypropylene, nitinol, or gold
  • History of anaphylaxis to contrast, with inability to prophylax appropriately.
  • Have uncorrectable coagulopathy
  • Have a body habitus that would inhibit X-ray visualization of the aorta
  • Have a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned ≤ 30 days of the endovascular repair
  • Known to be participating in any other clinical study which may affect performance of this device
  • Known, visible, or suspected pregnancy, confirmed with a Urine Pregnancy Test (UPT)
  • Contraindication to oral antiplatelet therapy
  • Prisoners or those on alternative sentencing
  • Known systemic infection with potential for endovascular graft infection
  • Anticipated need for MRI scanning within 3 months of insertion of investigational product
  • Other conditions or comorbidities that, in the opinion of the S-I, would exclude the patient

Where

  • New Haven, Connecticut
  • Lebanon, New Hampshire

Frequently asked questions

What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Data: ClinicalTrials.gov · synced Apr 27, 2026 · Source of record for eligibility and locations

📊
1 of 80 participants interested
1% interest

See if this study fits

A short prescreen based on this study's listed criteria. A coordinator confirms eligibility — this is not a medical assessment.

Preparing your pre-screening questions…

Study locations

Choose your preferred location, or select flexible during enrollment.

RECRUITING

New Haven

Connecticut

Location available
ACTIVE_NOT_RECRUITING

Lebanon

New Hampshire

Location available

Express your interest

Share your contact details and a study coordinator can follow up about screening.

Secure & Confidential

Your information is protected and will only be shared with the research team.

What participation can include

  • Study-related care provided by the research team
  • Close monitoring by medical professionals
  • Possible compensation for time and travel*
  • The option to withdraw at any time
  • Contributing to medical research that may help future patients

*Compensation varies by study. Confirm details with coordinator.

Typical next steps

  1. 1.Submit this form
  2. 2.Phone screening
  3. 3.In-person assessment if eligible
  4. 4.Begin participation

Find More Heart Attack Trials by City

Browse all heart attack clinical trials in these cities — not just this study.

Looking for Aortic Aneurysm, Thoracoabdominal Treatment in New Haven?

Join others in Connecticut exploring innovative treatment options through clinical research

Aortic Aneurysm, Thoracoabdominal Treatment Options in New Haven, Connecticut

If you're searching for Aortic Aneurysm, Thoracoabdominal treatment in New Haven, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in New Haven, Lebanon and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Aortic Aneurysm, Thoracoabdominal. All study-related care is provided at no cost to participants.

Local Sites
2 locations in Connecticut
Now Enrolling
Up to 80 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Aortic Aneurysm, Thoracoabdominal?

Potential Benefits

  • Access to new treatment approaches before public availability
  • Close monitoring by experienced medical professionals
  • Study-related care provided at no cost
  • Contribute to medical research for Aortic Aneurysm, Thoracoabdominal

What to Expect

  • Initial screening to determine eligibility
  • Regular check-ups and monitoring visits
  • Possible compensation for time and travel
  • You can withdraw at any time

Frequently Asked Questions About This Aortic Aneurysm, Thoracoabdominal Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT02989948. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.